Tranzyme release Phase IIb results with Ghrelin Agonist, TZP-101, for Postoperative Ileus (POI)

Tranzyme Pharma have released positive Phase IIb results for its ghrelin agonist, TZP-101, in the management of postoperative ileus (POI).

Tranzymes Ghrelin Agonist TZP-101 has safe QT/QTc Profile

Tranzyme Pharma has announced that its lead Ghrelin Agonist TZP-101 has a safe QT/QTc Profile

Elixirs Ghrelin agonist EX-1314 enhances gastric motility in vivo

Data presented at the Endocrine Society meeting show Elixir Pharmaceutical’s ghrelin agonist, EX-1314 to enhance gastrointestinal motility in vivo

Tranzymes Ghrelin Agonist TZP-102 completes phase I trial

Tranzyme have completed a phase I trial of its Ghrelin Agonist TZP-102 which has potenital in the treatment of mild-to-moderate gastroparesis.

Elixir present Ghrelin knockout mouse data further validating target

Data presented at the ADA meeting has further validated ghrelin, as a potential target in the treatment of diabetes. Data showed that Ghrelin knockout mice demonstrated a improved metabolic profile when placed on low and high fat diets compared to control mice.

Tranzyme to present data on Ghrelin agonist TZP-101 at ADA

Data to be presented at this weeks ADA meeting show Tranzyme’s Ghrelin Agonist TZP-101 to reduce gastric emptying in patients with diabetes and severe symptomatic gastroparesis.

Elixir publish data validating ghrelin as a key metabolic modulator

Elixir have publish data in the journal ‘Regulatory Peptides’ validating ghrelin as a key metabolic modulator. Elixir are developing ghrelin antagonists